RFA-DK-27-147: Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2026.
National Institutes of Health offered grants of up to $2.2 million to the applicants described in the notice. It expected to make one award worth $3.3 million in total. Applications closed on September 30, 2026.
From the official notice on Grants.gov, last changed May 20, 2026. Checked November 7, 2026.
- Award ceiling$2.2 million
- Total funding$3.3 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Clinical trialsNot allowed
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-27-147 in the NIH Guide.
Key dates
| Posted | May 20, 2026 |
|---|---|
| Deadline | September 30, 2026 |
| Archived by Grants.gov | November 29, 2026 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Only the PI/PDs associated with the award issued under RFA-DK-20-509 to Beckman Research Institute/City of Hope is eligible to apply for this single source funding. Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Past Diabetes, Digestive, and Kidney Diseases Extramural Research awards averaged $1.2 million; this notice allows up to $2.2 million per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-27-147 still open?
No. It closed on September 30, 2026.
Who can apply for Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)?
Closed September 30, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.2 million each. About $3.3 million in total for one award.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)